Amyloid-directed monoclonal antibodies for the treatment of Alzheimer’s disease: the point of no return?

Is there still any hope for amyloid-based immunotherapy for Alzheimerʼs disease?

(2014) Francesco Panza et al.   CURRENT OPINION IN PSYCHIATRY

Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward

(2014) Francesco Panza et al.   Expert Review of Clinical Immunology

Advances in the prevention of Alzheimer's disease and dementia

(2014) A. Solomon et al.   JOURNAL OF INTERNAL MEDICINE

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

(2014) L. S. Schneider et al.   JOURNAL OF INTERNAL MEDICINE

Lessons from immunotherapy for Alzheimer disease

(2014) Yan-Jiang Wang   Nature Reviews Neurology

Antiamyloid Therapy for Alzheimer's Disease — Are We on the Right Road?

(2014) Eric Karran et al.   NEW ENGLAND JOURNAL OF MEDICINE

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease

(2014) A. M. Fagan et al.   Science Translational Medicine

The A4 Study: Stopping AD Before Symptoms Begin?

(2014) R. A. Sperling et al.   Science Translational Medicine

Vascular Risk Factors

(2013) Jack C. de la Torre   American Journal of Alzheimers Disease and Other Dementias

Bapineuzumab and solanezumab for Alzheimer's disease: is the ‘amyloid cascade hypothesis' still alive?

(2013) Haythum O Tayeb et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

(2013) Victor L Villemagne et al.   LANCET NEUROLOGY

Immunotherapy for Alzheimer’s disease: hoops and hurdles

(2013) Cynthia A Lemere   Molecular Neurodegeneration

Review: Cerebral amyloid angiopathy, prion angiopathy, CADASIL and the spectrum of protein elimination failure angiopathies (PEFA) in neurodegenerative disease with a focus on therapy

(2013) R. O. Carare et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Regulatory Innovation and Drug Development for Early-Stage Alzheimer's Disease

(2013) Nicholas Kozauer et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

(2013) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial

(2013) S.M. Mills et al.   REVUE NEUROLOGIQUE

Changes in Amyloid-  and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor Protein

(2013) L. F. Maia et al.   Science Translational Medicine

Dominantly Inherited Alzheimer Network: facilitating research and clinical trials

(2013) Krista L Moulder et al.   Alzheimers Research & Therapy

Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?

(2013) Jens Moreth et al.   Immunity & Ageing

Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease

(2012) Martin Farlow et al.   Alzheimers & Dementia

Brain injury biomarkers are not dependent on β-amyloid in normal elderly

(2012) David S. Knopman et al.   ANNALS OF NEUROLOGY

Amyloid-β–Associated Clinical Decline Occurs Only in the Presence of Elevated P-tau

(2012) Rahul S. Desikan et al.   ARCHIVES OF NEUROLOGY

Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease

(2012) Henrik Zetterberg   ARCHIVES OF NEUROLOGY

Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease

(2012) Vladimir Coric et al.   ARCHIVES OF NEUROLOGY

Gantenerumab for the treatment of Alzheimer's disease

(2012) Julien Delrieu et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease

(2012) Bruno P Imbimbo et al.   Expert Review of Clinical Immunology

Immunotherapy for Alzheimer’s disease: from anti-β-amyloid to tau-based immunization strategies

(2012) Francesco Panza et al.   Immunotherapy

Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis

(2012) Jungsu Kim et al.   JOURNAL OF EXPERIMENTAL MEDICINE

An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A  Binding Properties Promotes Neuroprotection and Glial Engulfment of A 

(2012) O. Adolfsson et al.   JOURNAL OF NEUROSCIENCE

Preclinical Alzheimer disease—the challenges ahead

(2012) Reisa A. Sperling et al.   Nature Reviews Neurology

Deciphering the mechanism underlying late-onset Alzheimer disease

(2012) Dimitrije Krstic et al.   Nature Reviews Neurology

Immunization targeting a minor plaque constituent clears β-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model

(2012) Jose Morales-Corraliza et al.   NEUROBIOLOGY OF AGING

Passive Immunization against Pyroglutamate-3 Amyloid-ß Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study

(2012) Jeffrey L. Frost et al.   Neurodegenerative Diseases

Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease

(2012) D. S. Knopman et al.   NEUROLOGY

A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice

(2012) Ronald B. DeMattos et al.   NEURON

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy

(2011) Cheryl A. Hawkes et al.   ACTA NEUROPATHOLOGICA

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease

(2011) Clifford R. Jack et al.   ANNALS OF NEUROLOGY

Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab

(2011) Susanne Ostrowitzki   ARCHIVES OF NEUROLOGY

Anti-β-Amyloid Immunotherapy for Alzheimers Disease: Focus on Bapineuzumab

(2011) Francesco Panza et al.   Current Alzheimer Research

Autoreactive-Aβ antibodies promote APP β-secretase processing

(2011) Juan Deng et al.   JOURNAL OF NEUROCHEMISTRY

Testing the Right Target and Right Drug at the Right Stage

(2011) R. A. Sperling et al.   Science Translational Medicine

Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease

(2010) Eric R. Siemers et al.   CLINICAL NEUROPHARMACOLOGY

Towards Disease-Modifying Treatment of Alzheimers Disease: Drugs Targeting β -Amyloid

(2010) V. Frisardi et al.   Current Alzheimer Research

Antioxidant approaches for the treatment of Alzheimer’s disease

(2010) Hyun Pil Lee et al.   Expert Review of Neurotherapeutics

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Mechanisms of tau-induced neurodegeneration

(2009) Khalid Iqbal et al.   ACTA NEUROPATHOLOGICA

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

(2009) S. Salloway et al.   NEUROLOGY

Oligomeric amyloid   associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques

(2009) R. M. Koffie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain

(2008) D. Boche et al.   BRAIN